Liver Transplantation in Hepatocellular Carcinoma: Experiences from the Shiraz Transplant Center

Background: Studies evaluating liver transplantation (LT) in hepatocellular carcinoma (HCC) in the Middle East have been scarce, mainly due to intricacy of this type of surgery. Objective: In here we report our experiences with LT among patients with HCC cirrhosis. Methods: All patients who underwent LT with primary diagnosis of HCC older than 18 years old, during 2004 to 2019, were initially included in our study. Results: Overall, 124 patients entered our study, among which majority were males (86.3%). Mean (SD) age of patients was 53.1 +/- 10.6 years old. Most common underlying liver diseases were HBV (55.6%) and HCV infections (12.1%). Mean MELD score of patients was 18 +/- 5.5. Child-puge score of most patients was class B (50%). Mean (SD) duration of hospitalization was 12.1 +/- 3.5 days. Patients were followed for a median of 32 (9, 62) months. The most common causes of death were recurrence of HCC (47.7%) and sepsis (34.1%). Median (IQR) duration to recurrence and death were 18 (4, 34) months and 17.5 (5.7, 44.5) months, respectively. One-year survival (89%, 86.4%, and 63.2%, respectively) (p=0.011) and one year DFS (89%, 86.4%, and 57.9%, respectively) (p=0.001) was significant different between those who were selected based on the Milan, UCSF and extended criteria Conclusion: Our study provides valuable experiences on LT and HCC from one of the largest LT center in the world. Accordingly, we found that the Milan criterion provides the best survival compared to the UCSF and our extended criteria for patient selection.